文献速递胸部技术与安全DR

COVID-19疫苗对SARS-CoV-2重症感染相关临床与影像结局的随时间变化的有效性

Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection.
PubMed 文献 · Radiology · 2024-01-01

这项多中心回顾性研究纳入2021年6月至2022年12月因COVID-19住院的4196例患者,按距末次接种时间分组,评估疫苗对重症临床结局和重症影像学肺炎的有效性随时间的变化。结果显示,距诊断超过240天接种者重症临床结局和重症肺炎的比值比均高于90天内接种者,而91-240天接种者与90天内接种者无差异。

要点

  • 距末次接种超过240天者重症临床结局OR=1.94(95%CI 1.16,3.24;P=.01),高于90天内接种者。
  • 距末次接种超过240天者胸片重症肺炎OR=1.65(95%CI 1.13,2.40;P=.009),高于90天内接种者。
  • 距末次接种91-240天者与90天内接种者相比,重症临床结局和重症肺炎的比值比无显著差异。

核心结论

  • 疫苗对SARS-CoV-2感染相关重症临床结局和重症肺炎的有效性随时间逐渐下降,距诊断超过240天接种者两者的比值比均升高。

研究设计与样本

  • 多中心回顾性研究,纳入韩国COVID-19影像队列数据库中2021年6月至2022年12月因COVID-19住院的患者4196例(平均年龄66岁±17[SD];女性2132例[51%],男性2064例[49%]),按距诊断与末次接种的时间分组,采用校正多变量logistic回归估计疫苗有效性。

诊断标准与关键数值

  • 重症临床结局为有创通气、体外膜氧合或院内死亡的复合终点;重症影像学肺炎定义为肺部受累≥25%。距末次接种≤90天重症肺炎比例为18%(277/1527),91-120天为22%(172/783),121-180天为27%(274/1032),181-240天为32%(159/496),>240天为31%(110/358)。

临床应用与阅片要点

  • 阅片报告胸片肺部受累≥25%时,可结合距末次疫苗接种时间分层理解重症肺炎风险。
  • 距末次接种超过240天者,重症临床结局OR=1.94(95%CI 1.16,3.24;P=.01),高于90天内接种者。
  • 距末次接种超过240天者,胸片重症肺炎OR=1.65(95%CI 1.13,2.40;P=.009),高于90天内接种者。
  • 距末次接种91-240天者与90天内接种者相比,重症临床结局(P=.13至P=.68)和重症肺炎(P=.15至P=.86)的比值比无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The impact of waning vaccine effectiveness on the severity of COVID-19-related findings discovered with radiologic examinations remains underexplored. Purpose To evaluate the effectiveness of vaccines over time against severe clinical and radiologic outcomes related to SARS-CoV-2 infections. Materials and Methods This multicenter retrospective study included patients in the Korean Imaging Cohort of COVID-19 database who were hospitalized for COVID-19 between June 2021 and December 2022. Patients who had received at least one dose of a SARS-CoV-2 vaccine were categorized based on the time elapsed between diagnosis and their last vaccination. Adjusted multivariable logistic regression analysis was used to estimate vaccine effectiveness against a composite of severe clinical outcomes (invasive ventilation, extracorporeal membrane oxygenation, or in-hospital death) and severe radiologic pneumonia (≥25% of lung involvement), and odds ratios (ORs) were compared between patients vaccinated within 90 days of diagnosis and those vaccinated more than 90 days before diagnosis. Results Of 4196 patients with COVID-19 (mean age, 66 years ± 17 [SD]; 2132 [51%] women, 2064 [49%] men), the ratio of severe pneumonia since their most recent vaccination was as follows: 90 days or less, 18% (277 of 1527); between 91 and 120 days, 22% (172 of 783); between 121 and 180 days, 27% (274 of 1032); between 181 and 240 days, 32% (159 of 496); and more than 240 days, 31% (110 of 358). Patients vaccinated more than 240 days before diagnosis showed increased odds of severe clinical outcomes compared with patients vaccinated within 90 days (OR = 1.94 [95% CI: 1.16, 3.24]; P = .01). Similarly, patients vaccinated more than 240 days before diagnosis showed increased odds of severe pneumonia on chest radiographs compared with patients vaccinated within 90 days (OR = 1.65 [95% CI: 1.13, 2.40]; P = .009). No difference in odds of severe clinical outcomes (P = .13 to P = .68) or severe pneumonia (P = .15 to P = .86) were observed between patients vaccinated 91-240 days before diagnosis and those vaccinated within 90 days of diagnosis. Conclusion Vaccine effectiveness against severe clinical outcomes and severe pneumonia related to SARS-CoV-2 infection gradually declined, with increased odds of both observed in patients vaccinated more than 240 days before diagnosis. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Wells in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lee JE, Jin KN, Hong H, et al. Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection. Radiology. 2024. PMID: 38259210. doi:10.1148/radiol.231928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。